| Rachel Brozinsky, MD | |
|
2520 30th Ave Fl 4, Astoria, NY 11102-2448 | |
| (718) 808-7777 | |
| Not Available |
| Full Name | Rachel Brozinsky |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 2520 30th Ave Fl 4, Astoria, New York |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295077758 | NPI | - | NPPES |
| 04425930 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 283264 (New York) | Primary |
| Entity Name | North Shore Medical Group Of The Mount Sinai School Of Medicine |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275640609 PECOS PAC ID: 8921999087 Enrollment ID: O20040320000412 |
News Archive
Cancer Council Queensland is calling for enhanced joint efforts to improve Indigenous cancer control following the release of research findings that cancer survival is lower for Indigenous than non-Indigenous Australians for all cancers combined, and for many specific types of cancer.
Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has requested and been granted a Type B pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding its RIGS® technology Biologic License Application (BLA). The pre-IND meeting request is another step in Neoprobe's efforts to develop and commercialize the RIGS technology designed to enhance the surgical treatment of patients with solid tumor cancers.
The European Union has funded a 4 year project called TAILORED-Treatment with € 6.000.000,-. The main goal of TAILORED -Treatment is to establish a strategy that can be used to increase the effectiveness of antibiotic treatment, reduce any potential side-effects of therapy, and help limit the emergence of antimicrobial resistance in hospitalized children and adults. The project will be coordinated by Erasmus MC, Rotterdam, the Netherlands.
2009 estimates projected that in the United States alone 21,550 new cases of ovarian cancer would be diagnosed and 14,600 women would die of the disease. Often diagnosed in late stages, ovarian cancer has an asymptomatic onset and a relatively low 5-year survival rate of about 45%. Consequently investigation linked to survivorship is critical.
› Verified 1 days ago
| Entity Name | Icahn School Of Medicine At Mount Sinai |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477932275 PECOS PAC ID: 2264691070 Enrollment ID: O20150811003333 |
News Archive
Cancer Council Queensland is calling for enhanced joint efforts to improve Indigenous cancer control following the release of research findings that cancer survival is lower for Indigenous than non-Indigenous Australians for all cancers combined, and for many specific types of cancer.
Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has requested and been granted a Type B pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding its RIGS® technology Biologic License Application (BLA). The pre-IND meeting request is another step in Neoprobe's efforts to develop and commercialize the RIGS technology designed to enhance the surgical treatment of patients with solid tumor cancers.
The European Union has funded a 4 year project called TAILORED-Treatment with € 6.000.000,-. The main goal of TAILORED -Treatment is to establish a strategy that can be used to increase the effectiveness of antibiotic treatment, reduce any potential side-effects of therapy, and help limit the emergence of antimicrobial resistance in hospitalized children and adults. The project will be coordinated by Erasmus MC, Rotterdam, the Netherlands.
2009 estimates projected that in the United States alone 21,550 new cases of ovarian cancer would be diagnosed and 14,600 women would die of the disease. Often diagnosed in late stages, ovarian cancer has an asymptomatic onset and a relatively low 5-year survival rate of about 45%. Consequently investigation linked to survivorship is critical.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Rachel Brozinsky, MD 2520 30th Ave Fl 4, Astoria, NY 11102-2448 Ph: (718) 808-7777 | Rachel Brozinsky, MD 2520 30th Ave Fl 4, Astoria, NY 11102-2448 Ph: (718) 808-7777 |
News Archive
Cancer Council Queensland is calling for enhanced joint efforts to improve Indigenous cancer control following the release of research findings that cancer survival is lower for Indigenous than non-Indigenous Australians for all cancers combined, and for many specific types of cancer.
Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has requested and been granted a Type B pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding its RIGS® technology Biologic License Application (BLA). The pre-IND meeting request is another step in Neoprobe's efforts to develop and commercialize the RIGS technology designed to enhance the surgical treatment of patients with solid tumor cancers.
The European Union has funded a 4 year project called TAILORED-Treatment with € 6.000.000,-. The main goal of TAILORED -Treatment is to establish a strategy that can be used to increase the effectiveness of antibiotic treatment, reduce any potential side-effects of therapy, and help limit the emergence of antimicrobial resistance in hospitalized children and adults. The project will be coordinated by Erasmus MC, Rotterdam, the Netherlands.
2009 estimates projected that in the United States alone 21,550 new cases of ovarian cancer would be diagnosed and 14,600 women would die of the disease. Often diagnosed in late stages, ovarian cancer has an asymptomatic onset and a relatively low 5-year survival rate of about 45%. Consequently investigation linked to survivorship is critical.
› Verified 1 days ago
Yaxi Chen, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 3014 37th St, Astoria, NY 11103 Phone: 718-278-9500 | |
Mr. Christodoulos Iordanou, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 3711 23rd Ave, Astoria, NY 11105 Phone: 718-721-6166 | |
Lilly Rodriguez, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 2922 30th Ave, Astoria, NY 11102 Phone: 718-545-2500 Fax: 718-777-1369 | |
Dr. Arthur John Deluca, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 3014 37th St, Third Floor, Astoria, NY 11103 Phone: 718-288-1474 Fax: 888-356-2653 | |
Tran Lam Huynh, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 2552 Steinway St, Astoria, NY 11103 Phone: 646-429-2190 | |
Dr. Michael Iordanou, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 3711 23rd Ave, Astoria, NY 11105 Phone: 718-721-6166 Fax: 718-721-7237 | |
Dr. Oscar Chamudes, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 3187 Steinway St Ste 6, Astoria, NY 11103 Phone: 718-626-4881 Fax: 718-626-5102 |